GlassScriptPhysician profile
James Anthony Michail
NPI 1760879217
$1,431.36
in general payments reported to CMS, 2019-2025
23 companies · $320 in 2025
The $320 reported for 2025 was more than what a typical Geriatric Medicine (Family Medicine) provider received nationally (typical 2025 total: $119).
See the full distribution for Geriatric Medicine (Family Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $479 · 2020: $89.26 · 2021: $41.63 · 2022: $213 · 2023: $100 · 2024: $188 · 2025: $320.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $609.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $608.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka Pharmaceutical Development & Commercialization, INC. | $234.97 | 2025 | Rexulti |
| Amgen INC. | $173.40 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $168.32 | 2023-2025 | Rexulti |
| Angiodynamics, INC. | $159.66 | 2022 | |
| Cardiovascular Systems INC. | $133.27 | 2019 | |
| Radius Health, INC. | $58.77 | 2019 | |
| Intuitive Surgical, INC. | $56.38 | 2024 | |
| Sun Pharmaceutical Industries INC. | $40.77 | 2019-2021 | |
| Pfizer INC. | $40.17 | 2025 | |
| Glaxosmithkline, LLC. | $38.87 | 2019 | |
| Novartis Pharmaceuticals Corporation | $38.41 | 2019-2020 | |
| Abbvie INC. | $37.14 | 2019-2023 | |
| Acadia Pharmaceuticals INC | $32.22 | 2020-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $31.60 | 2019 | |
| Neurocrine Biosciences, INC. | $30.96 | 2023 | Ingrezza |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viatris Specialty LLC | $27.48 | 2025 | Yupelri |
| Astrazeneca Pharmaceuticals LP | $23.74 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $19.14 | 2019 | |
| Sunovion Pharmaceuticals INC. | $19.06 | 2022 | |
| Dexcom, INC. | $17.68 | 2024 | Dexcom G6 Transmitter |
| Urovant Sciences INC | $16.87 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.41 | 2024 | |
| Allergan, INC. | $16.07 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Michail listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.